Meeting
2011 ASCO Annual Meeting
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
Authors
H. Kantarjian
University of Texas M. D. Anderson Cancer Center, Houston, TX
H. Kantarjian , N. P. Shah , J. E. Cortes , M. Baccarani , M. B. Bradley-Garelik , C. Zhu , A. Hochhaus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00481247
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6510)
Abstract #
6510
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
First Author: James E. Signorovitch
Poster
2019 ASCO Annual Meeting
Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).
First Author: Kiran Naqvi
Poster
2017 ASCO Annual Meeting
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.
First Author: Jorge E. Cortes
Poster
2013 ASCO Annual Meeting
EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.
First Author: Jeffrey H. Lipton